{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:27:15Z","timestamp":1771921635343,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Planning Projects of Guangzhou","award":["202102021259"],"award-info":[{"award-number":["202102021259"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Primary fallopian tube carcinoma (PTC) is a rare epithelial malignancy of gynecologic origin. The adenosquamous carcinoma variant with\n                      <jats:italic>POLE<\/jats:italic>\n                      mutations is particularly uncommon, and current treatment strategies are limited by its elusive pathogenesis. Given similarities in biological behavior and clinical characteristics to ovarian cancer, PTC staging and management follow ovarian cancer guidelines. Previous studies suggest that anti-angiogenic therapy and poly (ADP-ribose) polymerase (PARP) inhibitors may be potential therapeutic options.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a case of bilateral PTC exhibiting histologic heterogeneity and a\n                      <jats:italic>POLE<\/jats:italic>\n                      mutation, complicated by pelvic recurrence with bilateral lung metastases and sigmoid colon involvement. Partial response (PR) was achieved after six cycles of albumin-bound paclitaxel plus carboplatin (nab-TC) combined with bevacizumab (Bev), followed by maintenance therapy with the PARP inhibitor niraparib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that Bev combined with chemotherapy may be an effective first-line regimen for this rare PTC variant. Maintenance therapy with a PARP inhibitor may prolong progression-free survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1696996","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:48:07Z","timestamp":1771915687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Bevacizumab combined with chemotherapy followed by PARP inhibitor maintenance therapy in POLE-mutated primary fallopian tube carcinoma: a case of precision treatment in a rare gynecologic malignancy"],"prefix":"10.3389","volume":"13","author":[{"given":"Donghai","family":"Cheng","sequence":"first","affiliation":[{"name":"People\u2019s Liberation Army General Hospital of Southern Theatre Command","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Huang","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army General Hospital of Southern Theatre Command","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army General Hospital of Southern Theatre Command","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujie","family":"Liu","sequence":"additional","affiliation":[{"name":"Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham","place":["Ningbo, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyuan","family":"He","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army General Hospital of Southern Theatre Command","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1634\/theoncologist.11-8-902","article-title":"Fallopian tube carcinoma: a review","volume":"11","author":"Pectasides","year":"2006","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41436-020-0828-z","article-title":"Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction","volume":"22","author":"Hamzaoui","year":"2020","journal-title":"Genet Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/CMAR.S445055","article-title":"The clinical and pathological characteristics of POLE-mutated endometrial cancer: a comprehensive review","volume":"16","author":"Yao","year":"2024","journal-title":"Cancer Manag Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2021.03.017","article-title":"Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: a pooled analysis from five international centres","volume":"155","author":"Bissonnette","year":"2021","journal-title":"Lung Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2019.05.016","article-title":"Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma","volume":"154","author":"Nasioudis","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2301801","DOI":"10.1080\/15384047.2024.2301801","article-title":"The critical role of tumor microbiome in cancer immunotherapy","volume":"25","author":"Yang","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-024-01939-5","article-title":"A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon\/polymerase delta (POLE\/POLD1) mutation","volume":"9","author":"Jin","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ijc.33966","article-title":"Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high\/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer","volume":"150","author":"Oh","year":"2022","journal-title":"Int J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6512073","DOI":"10.1155\/2024\/6512073","article-title":"Unveiling the hidden burden: exploring the psychological impact of gynecological cancers and predictive modeling of depression in Southwest China","volume":"2024","author":"Sun","year":"2024","journal-title":"Depress Anxiety"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1101\/gad.351084.123","article-title":"Atr inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy","volume":"37","author":"Wang","year":"2023","journal-title":"Genes Dev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1682846","DOI":"10.3389\/fimmu.2025.1682846","article-title":"Comprehensive analysis of metabolism-related genes in sepsis reveals metabolic-immune heterogeneity and highlights Gyg1 as a potential therapeutic target","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1696996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:48:08Z","timestamp":1771915688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1696996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1696996"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1696996","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1696996"}}